FDA moves toward tougher gluten labeling rules

The FDA said that "serious data gaps" have hindered its ability to craft regulation, including a lack of information on ...

What to know about FDA's review of new Zyn advertising proposal

Americans who smoke may soon be hearing a lot more about Zyn, the flavored nicotine pouches that have generated billions in ...
Parade on MSN

FDA issues highest risk recall for grated cheese linked to listeria concerns

It was sold at Sam's Club, Meijer and more.

The FDA's Hands-Off Approach to Medical AI Is a Win for Health-Conscious Consumers

AI-powered medical wearables and software are flourishing following the FDA’s new hands-off regulatory guidance.

FDA commissioner explains new food pyramid, encourages greater uptake of core childhood vaccines

Martin Makary, commissioner of the Food and Drug Administration, on the push against ultra processed foods and added sugar, ...

Legal questions swirl around FDA’s new expedited drug program, including who should sign off

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

Takeaways from the AP’s report on turmoil surrounding the FDA’s new fast-track drug program

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
FOX 35 Orlando

FDA approves drug to treat dogs with idiopathic epilepsy

The U.S. Food and Drug Administration (FDA) has approved a drug to control seizures in dogs with idiopathic epilepsy, a type ...
Becker's Hospital Review

FDA eases approval path for cell, gene therapies

The FDA has updated guidance outlining how it applies regulatory flexibility to chemistry, manufacturing and control requirements for cell and gene therapies. The agency said the approach is meant to ...

Tuna Recalled Over Botulism Concerns Still on Shelves, FDA Reports

Here’s a list of impacted products.
Becker's Hospital Review

Drug approvals to watch in 2026

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...